Literature DB >> 16684275

Atopic eczema: what's new?

M Möhrenschlager1, U Darsow, C Schnopp, J Ring.   

Abstract

Atopic eczema (AE) is a chronic inflammatory skin disease characterized by recurrent intense pruritus and a typical age-related distribution of skin lesions. Several new aspects with regard to the pathogenetic background as well as strategies for prevention, diagnosis and treatment of AE have emerged. There are ongoing studies on genetic susceptibility loci, as well as environmental and nutritional factors associated with an increase or a decrease of AE lesions. The atopy patch test is now available for identification of allergens in aeroallergen-triggered AE. New topical therapies, such as the calcineurin inhibitors, have broadened the therapeutic armamentarium substantially. In order to increase knowledge and coping strategies, patient education programs have been launched. Learning objective Upon completing this paper, the reader should be aware of new developments in AE, especially on nomenclature, prevention strategies, diagnostic tests, as well as therapeutic options.

Entities:  

Mesh:

Year:  2006        PMID: 16684275     DOI: 10.1111/j.1468-3083.2006.01580.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  5 in total

1.  Preliminary Comparison of the Efficacy and Safety of Needle-Embedding Therapy with Acupuncture for Atopic Dermatitis Patients.

Authors:  Ho-Chan Lee; Soo-Yeon Park
Journal:  Evid Based Complement Alternat Med       Date:  2019-04-23       Impact factor: 2.629

Review 2.  Systemic therapy of atopic dermatitis in children.

Authors:  Giampaolo Ricci; Arianna Dondi; Annalisa Patrizi; Massimo Masi
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  Emollients and moisturisers for eczema.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Robin Christensen; Adriana Lavrijsen; Bernd WM Arents
Journal:  Cochrane Database Syst Rev       Date:  2017-02-06

Review 4.  Role of primary and secondary prevention in atopic dermatitis.

Authors:  Magdalena Oszukowska; Iwonna Michalak; Katarzyna Gutfreund; Wojciech Bienias; Marta Matych; Anna Szewczyk; Andrzej Kaszuba
Journal:  Postepy Dermatol Alergol       Date:  2015-12-11       Impact factor: 1.837

5.  Evaluation of the efficacy and safety of a Chinese herbal formula (RCM-106) for atopic dermatitis: study protocol for a randomised, double-blind, placebo-controlled trial in children.

Authors:  Hsiewe Ying Tan; Anthony L Zhang; Charlie C Xue; Dacan Chen; Cliff Da Costa; George B Lenon
Journal:  BMJ Open       Date:  2013-12-30       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.